Pfizer's Covid vaccine is 85% effective after one dose and blocks 75% of transmission, Israeli study finds in huge boost to UK's decision to delay second injection

• tudy of 9,000 health workers found one jab stopped 85% of people falling sick 
• Single injection also blocked 75% of participants from asymptomatic infection
• UK drew criticism in January when it pushed back the second dose to 12 weeks

  iew comments

  

  +2

  Pfizer/BioNTech's coronavirus vaccine is 85 per cent effective after the first dose, according to an Israeli study

  Pfizer/BioNTech's coronavirus vaccine is 85 per cent effective after the first dose, according to an Israeli study that bolsters Britain's decision to delay the second injection. 

  The UK drew criticism in January when it pushed back the second dose from three weeks to three months because the jabs were never trialled using that dosing regimen. 

  But the latest research on 9,000 healthcare workers, published in The Lancet, found that a single shot reduced the number of people developing symptomatic Covid by 85 per cent after three weeks. 

  Separate research by Pfizer/BioNTech published today showed their vaccine can now be stored at the same temperature as a household freezer (-15C to -25C) for two weeks. The company has submitted its results to the US-based Food and Drug Administration (FDA) to approve the change to shipping requirements, reports the Financial Times, with experts saying it's likely the pharmaceutical giant has now had enough time to test the jab at different temperatures.The study by the Sheba Medical Centre, one of Israel's top research hospitals, reported a 75 per cent drop in the number of people testing positive for the infection, suggesting the single shot will have a significant impact on blocking asymptomatic infection and transmission.

  A positive PCR swab would signal that even someone who is vaccinated is carrying fragments of the virus in their nose or throat which they could pass on. Reducing Covid's spread is critical for country's to achieve 'herd immunity', when so many people are immune that a disease peters out. 

  Lead researcher Professor Arnon Afek, deputy director-general at Sheba, said: 'This groundbreaking research supports the British government's decision to begin inoculating its citizens with a single dose of the vaccine.' 

  The UK has also been spacing out Oxford University's vaccine doses in a bid to get better coverage quicker, with the nation in a race against time to vaccinate as many vulnerable Britons as possible before the end of March.

  An Oxford study earlier this month found a single shot of that jab was 76 per cent effective for 12 weeks at stopping symptomatic disease and blocks seven in 10 people from spreading it.

  Israel's vaccine rollout is largest real-world study of Pfizer vaccine

  Loaded: 0%

  Progress: 0%

  0:00

  Previous

  Play

  Skip

  Mute

  Current Time0:00

  /

  Duration Time3:55

  Fullscreen

  Need Text

  Sheba epidemiologist Gili Regev-Yochay cautioned that the cohort studied at the hospital were 'mostly young and healthy'.  

  Unlike with Pfizer's clinical trial, 'we don't have many (staff) here aged over 65,' she told reporters. 

  But she also noted that the Sheba study took place during a surge in Covid-19 infections in Israel, which flooded hospitals with new cases.

  Pfizer declined to comment on the data, saying in a statement it was doing its own analysis of 'the vaccine´s real-world effectiveness in several locations worldwide, including Israel'.

  It hopes to use Israeli data to look at the potential of the vaccine to protect against Covid-19 arising from emerging variants, the drugmaker said.

  Pfizer's original trial of the vaccine found efficacy was 95 per cent if two doses were given 21 days apart. 

  Other countries including Israel and the US are trying to stick more closely to the three-week gap proven in the clinical trial.

  It comes after England's Covid vaccine postcode lottery was laid bare last night.

  It emerged parts of London have jabbed just 60 per cent of over-70s - while almost every elderly person has had their first dose in one district in Hampshire.

  The NHS England statistics, which go up to February 14, also show that some parts of the country have dished out nearly 300 times as many second doses as others.

  The capital was hardest hit by the lottery overall, accounting for the worst 10 areas for uptake. 

  Bottom of the pile was Westminster, in the city centre, where only 60.9 per cent of residents over 70 have had their first injection. West London was second, where 67.5 per cent in the same age group have been jabbed.

  On the other hand, North East Hampshire and Farnham which had got 99.8 per cent of its over-70s their first doses, the highest level in the country. 

  East Leicestershire and Rutland was second, at 99.3 per cent. Somerset and Sunderland have both also jabbed more than 99 per cent of over-70s with either Pfizer's or Oxford's vaccine. 

  Health chiefs fear vaccine hesitancy among black, Asian and ethnic minority (BAME) groups is behind the poorer uptake in London's culturally diverse boroughs. It follows reports of GP surgeries in London having to close early because not enough people have been turning up to get their injection.  

  The figures do not take into account health and social care staff or extremely clinically vulnerable younger people, such as those with terminal illnesses, who are both also at the top of the vaccine priority list. Instead, they look solely at over-70s, who are most at risk of dying from the illness.  

  Britain has already vaccinated more than 16million people and ministers have pledged to dish out jabs to all 32million in the top nine groups by April. 

  With the Government taking a cautious approach to easing lockdown this time around, it is widely accepted that all of the nine top vulnerable groups will need to have had at least one dose of vaccine before curbs can be significantly eased. 

  Pfizer/BioNTech vaccine CAN be stored at same temperature as household freezer results show 

  The Pfizer/BioNTech vaccine can be stored at the same temperature as a household freezer, results show, in a dramatic change bound to turbo-charge the doses rollout. 

  The pharmaceutical companies have submitted their study to the US-based Food and Drug Administration (FDA) for approval, reports the Financial Times.

  Stability data shows the shots store just as well when kept at normal freezer temperatures (-15C to -25C) as they do when at ultra-cold levels (-60C to -80C).

  Current requirements say they must be kept at the ultra-cold temperatures, which has led to countries building specialist supply chains using dry ice to distribute the jabs.

  But allowing them to be moved at warmer temperatures means industrial freezers can now accommodate them, and opens the door to a faster rollout in third world countries.

  The jabs will still need to be defrosted before they are used.

  Professor Peter English, an infectious diseases expert, said he thought it was likely the companies had been unable to test their jab being stored at different temperatures before it was distributed.

  'My guess would be that they store the product that way (ultra-cold temperatures) in their research facilities, and had not been able to do the necessary testing in time, prior to release as soon as possible so the product could be used, to ensure that lower temperature storage would suffice'.

  Single shot of Oxford University's Covid jab'is 76% effective for 12 weeks  

  A single shot of Oxford University's coronavirus vaccine is 76 per cent effective at preventing symptomatic illness and may have a 'substantial effect' on transmission, research suggests. 

  In a huge boost to the UK's immunisation drive, analysis of the jab trials found the first dose was extremely successful in preventing people from falling ill within the 12-week time window between getting a second dose.  

  When the second dose is administered after three months, the jab's efficacy is bumped up to 82.4 per cent, according to the study, which has been submitted to The Lancet for publication.  

  The results, from more than 17,000 trial volunteers, suggest Britain's vaccination gamble to delay its dosing regimen has paid off. 
  

  Another significant finding in the Oxford study is that the vaccine is likely to significantly reduce transmission of the virus.

  PCR swabs showed there was a 67 per cent reduction in positive tests in those who had been vaccinated - in another sign the UK's inoculation gamble has paid off.

• 
  

•